All relevant data are in the paper and in the Supporting information.

Introduction {#sec006}
============

The occurrence of Penile Cancer (PC) varies worldwide. In developed countries, PC has a low incidence, corresponding to 0.3--1% of malignant neoplasms in men. In some developing countries, the incidence of PC may be much higher than the global average incidence \[[@pone.0232474.ref001]--[@pone.0232474.ref003]\]. In Brazil, PC accounts for approximately 2.1% of all tumors in men being the highest incidence reported in the Latin America (2.9--6.8 cases per 100,000 men-years) \[[@pone.0232474.ref003]\]. We can find regional rate differences along the country. In the North and Northeast of Brazil, PC incidence is five times higher compared to the Midwest, South and Southeast regions \[[@pone.0232474.ref004]\]. According to the Brazilian National Cancer Institute (INCA), the death rate from PC in the northern region of Brazil has doubled in the last decade, from 0.05% to 0.10% \[[@pone.0232474.ref005]\].

PC is a multifactorial disease and the risk factors and/or favorable conditions to develop PC are not fully established. Phimosis and smegma accumulation are observed in more than 80% of the patients with PC associated with chronic inflammation process \[[@pone.0232474.ref006],[@pone.0232474.ref007]\]. Other factors, such as smoking and sexually transmitted infection, are also related to the onset of neoplasms \[[@pone.0232474.ref007],[@pone.0232474.ref008]\]. HPV infection is present in approximately 50% of PC cases and the most prevalent genotype is HPV16 (30%) \[[@pone.0232474.ref007],[@pone.0232474.ref009]--[@pone.0232474.ref011]\]. A recent meta-analysis study of 52 studies showed a pooled prevalence of 50.8% (44.8--56.7) of HPV infection in PC with a rate of 68.3% (58.9--77.1) of HPV16 \[[@pone.0232474.ref012]\].

The role played by HPV in carcinogenesis of the penis appears to be similar to cervical cancer. HPV encodes the E6 and E7 oncogenes which are required for malignant transformation and maintenance of host cells. The viral oncoproteins (E6 and E7) may compromise the regulation of the host cell cycle and lead to an uncontrolled proliferation \[[@pone.0232474.ref013],[@pone.0232474.ref014]\]. P16 is a tumor suppressor gene and its protein is physiologically expressed in normal tissues. The inactivation of the retinoblastoma gene (pRb) by HPV E7 results in overexpression of p16^INK4a^ due to the lack of negative feedback loop between pRb and p16 protein \[[@pone.0232474.ref015]\]. The overexpression of p16^INK4a^ in tumor cells has been shown to correlate with high-risk HPV DNA detection in PC \[[@pone.0232474.ref016]\].

Epstein-Barr virus (EBV) is another agent associated with PC \[[@pone.0232474.ref017],[@pone.0232474.ref018]\]. Inappropriate expression of its latent genes (Latent Membrane Protein) LMP-1, LMP-2A e LMP-2B, involved in cell persistence, may contribute to the development of tumors \[[@pone.0232474.ref019]\]. EBV is suggested as a viral cofactor rather than a primary carcinogen in Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma \[[@pone.0232474.ref017],[@pone.0232474.ref020]\]. In HPV-associated cancer, the presence of EBV may also act as a viral cofactor \[[@pone.0232474.ref021]\]. Several studies have shown the presence of EBV and co-infection with HPV in PC but a relationship between PC and EBV is yet to be established \[[@pone.0232474.ref017],[@pone.0232474.ref018]\].

In light of the possible roles of HPV and EBV infection in the development of PC, this study investigated p16^INK4a^ expression and HPV and EBV infection in a series of patients with PC from the Brazilian Amazon region.

Materials and methods {#sec007}
=====================

Enrollment {#sec008}
----------

A total of 47 patients with PC and no concomitant urological neoplastic diseases participating in the study were attended at the public reference cancer center hospital---Fundação Centro de Controle de Oncologia do Estado do Amazonas/FCECON from 2013 to 2018. The patients were followed at the Urology clinic of the hospital. All patients were surgically treated by total or partial penectomy.

All patients provided written informed consent and were interviewed to fill a questionnaire concerning sociodemographic data and risk factors. Histopathology characteristics of the tumors were obtained from the medical charts.

This study was approved by the internal review board of the Ethics Committee of the FCECON---approval document \#2.230.007, August 21, 2017. SISGEN- A5F36C5.

Biological samples collection {#sec009}
-----------------------------

At the moment of surgery, three to five mm^3^ of tissue fragments (mass of 50-150mg) from the tumor were collected and stored in a dry plastic microtube free of DNAse and RNAse. Samples were stored at -30 °C until processed.

DNA extraction {#sec010}
--------------

DNA was extracted from the frozen tissue (mass of 20-40mg from different parts of the tumor) using the DNeasy^®^ Blood & Tissue Kit (QIAGEN Inc., USA), according to the manufacturer's recommendations. The DNA was eluted in a volume of 200 μL UltraPure^™^ DNase/RNase-Free Distilled Water (Invitrogen Life Technologies, São Paulo, Brazil).

Human β-globin PCR {#sec011}
------------------

For DNA extraction quality control, the human β-globin gene was amplified by PCR as previously described in the literature with the following pair of primers: GH20: (`5’GAAGAGCCAAGGACAGGTAC’3`) and PCO4: (`5’CAACTTCATCCACGTTCACC’3`) generating a 270 bp DNA fragment \[[@pone.0232474.ref022]\].

HPV detection {#sec012}
-------------

All samples were submitted to generic HPV PCR using the consensus primers (PGMY09/11) which amplifies a 450 bp DNA fragment within the L1 region of mucosal HPVs \[[@pone.0232474.ref023]\]. Amplification was carried out as previously described using 50--100 ng of DNA in 25 μL of reaction mixture and a thermocycling profile of 1 cycle at 5 min at 95 °C, followed by 40 cycles: 1 min at 95 °C, 1 min at 55°C, and 1 min at 72 °C, with a final extension for 10 min at 72 °C. The PCR products (450 bp DNA) were analyzed on 1.5% agarose gel stained with SYBR^™^ Safe DNA Gel Stain (Invitrogen Life Technologies, São Paulo, Brazil) for visualization of DNA under UV light and 100 bp DNA ladder was used as molecular weight control pattern. Precautions to avoid contamination were followed. DNA from the HeLa cell line which harbors 10--20 copies of integrated HPV 18 per cell was used as a positive control in all reactions.

### E7 HPV16/HPV18 type-specific real-time PCR {#sec013}

All samples were also submitted to two specific TaqMan based real-time qPCR assays targeting either HPV16/HPV18 E7 gene in an ABI 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA). All samples and controls were run in duplicate.

### HPV16-E7 {#sec014}

qPCR assay included the following primers: forward (`5’GATGAAATAGATGGTCCAGC3’`) and reverse (`5’GCTTTGTACGCACAACCGAAGC3’`) primers, and the probe (5'FAM-`CAAGCAGAACCGGACAG`-MGB-NFQ) in a final reaction volume of 25 μL \[[@pone.0232474.ref024]\]. Each qPCR reaction contained 1X TaqMan master mix (Applied Biosystems, Foster City, CA), 400 nM each of the forward and reverse primers, 200 nM of fluorogenic TaqMan probe, and 50--100 ng of DNA. The amplification conditions consisted of 50 °C for 2 min and 95°C for 10 min, followed by 40 cycles of 95 °C for 15 sec, 55 °C for 1 min, and 60 °C for 1 minute. DNA from a SiHa cell line which contains 1--2 copies of integrated HPV 16 per cell was used as a positive control in all reactions.

### HPV18-E7 {#sec015}

qPCR assay included the following primers: forward (`5’AAGAAAACGATGAAATAGATGGA3’`) and reverse (`5’GGCTTCCACCTTACAACACA3’`) primers, and a probe (5'VIC-`AATCATCAACATTTACCAGCC`-MGBNFQ3') in a final reaction volume of 25 μL, each qPCR contained 1X TaqMan master mix (Applied Biosystems, Foster City, CA), 400 nM each of the forward and reverse primers, 400 nM fluorogenic TaqMan probe, and 50--100 ng of DNA \[[@pone.0232474.ref024]\]. The amplification conditions consisted of 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 50°C for 1 min, and 60°C for 1 min. DNA from the HeLa cell line which harbors 10--20 copies of integrated HPV 18 per cell was used as a positive control in all reactions.

### HPV genotyping---PapilloCheck^®^ HPV-Screening {#sec016}

All samples that were positive in generic HPV DNA (PGMY09/11) and negative for 16/18 genotypes were submitted to HPV-Screening Test (Greiner Bio-One GmbH, Frickenhausen, Germany) to identify other genotypes. This is a PCR-based DNA microarray system for detection and identification of 24 HPV genotypes, including 16 high-risk HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,58, 59, 68, 70, 73, 82), 2 probable high-risk HPV genotypes (HPV 53,66) and 6 low-risk-HPV genotypes (HPV 6, 11, 40, 42, 43, 44/55) \[[@pone.0232474.ref025]\].

EBV detection {#sec017}
-------------

EBV DNA detection was performed as described elsewhere \[[@pone.0232474.ref026]\]. Briefly, a sensitive multiplex PCR which amplifies 182 bp within the Exons 4/5 from the terminal protein RNA of EBV and a fragment of human β-actin 450 bp as internal control. The following pairs of primers for PCR amplification were used: EP5-`AACATTGGCAGCAGGTAAGC` and EM3 -`ACTTACCAAGTGTCCATAGGAGC` for EBV and B-ACT F--`TCTACAATGAGCTGCGTGTG` and B-ACT R -`CATCTCTTGCTCGAAGTC` for β-actin. PCR was performed as follows: 1 cycle at 5 min at 95°C, followed by 10 cycles of 30 sec at 95°C, 60 sec at 63°C and subsequently by 30 cycles of 30 sec at 95°C, 30 sec at 60°C, and 30 sec at 72°C, with a final extension for 40 sec at 72°C. PCR products were analyzed on 1.8% agarose gel stained with SYBR^™^ Safe DNA Gel Stain (Invitrogen Life Technologies, São Paulo, Brazil) for visualization of DNA under UV light and 100 bp DNA ladder was used as molecular weight control pattern. An EBV positive known sample from the laboratory was used as control.

Immunohistochemistry for p16^INK4a^ {#sec018}
-----------------------------------

Twenty six samples from PC patients, spotted in tissue microarray were submitted to the immunohistochemistry (IHC) assay for qualitative detection of the p16^INK4a^ (21 samples were not available due to pre-analytical factors). IHC assay was performed in an automated system using the Ventana^®^ BenchMark Ultra according to the manufacturer's instructions. The IHC slides were analyzed by a pathologist. Positivity for p16^INK4a^ was defined as unequivocally nuclear and cytoplasmic staining of at least 70% of the tumor cells \[[@pone.0232474.ref027],[@pone.0232474.ref028]\].

Statistical analysis {#sec019}
--------------------

Data were compiled using Epi Info^™^ version: 7.2.2.2 and analyzed using Stata application (v.13, StataCorp, 2013, College Station, Texas, USA). Descriptive analyses were performed using frequency tables. In this study, we analyze independently the relationship between the sociodemographic and clinical profile of patients with PC and three different outcomes: (i) p16^INK4a^ overexpression, (ii) HPV infection status and (iii) EBV infection status. Univariate logistic regression models were used to analyze the relationship between these outcomes and sociodemographic and clinical profile of patients with PC and calculate the odds ratios. A *p*-value \<0.05 was considered statistically significant.

Those variables that presented an association at a level of significance of 0.2 in the univariate logistic regression were selected to perform the multiple logistic regression. Multiple logistic regression models were used to identify the independent relationships between clinical characteristics of the patients and the studied outcomes. In this manner, adjusted odds ratios were calculated. A *p*-value \<0.05 was considered statistically significant.

Kaplan-Meier method was used to determine the differences between survival time of patients stratified by HPV and EBV infection, and with p16^INK4a^ overexpression. Groups were compared using the log rank test, taking a *p*-value less than 0.05 as statistically significant.

Results {#sec020}
=======

HPV and EBV were investigated in tumor tissues from 47 patients with PC, aged 20 to 90 years old (mean 57.4 years ±SD 17.8). Ten patients were below the age of 39 (21%). 64% of the patients came from rural areas of the Amazonas State, 23% from Manaus, the capital city and 13% from other Northern states of Brazil. 79% of the patients with PC were Amerindians descendent (mestizo) and 83% had less than eight years of schooling. 32% of the patients had total penectomy and 68% had partial penectomy. Lymphadenectomy was performed in 13/47 (28%) patients ([Table 1](#pone.0232474.t001){ref-type="table"}).

10.1371/journal.pone.0232474.t001

###### Sociodemographic characteristics of patients diagnosed with penile cancer at Amazon---Brazil.

![](pone.0232474.t001){#pone.0232474.t001g}

  Variables                                                     n    \%
  ------------------------------------------------------------- ---- ----
  **Age at diagnosis**                                               
  **Mean age** 57,4 (SD 17.8) **(n = 47)**                           
  18--39                                                        10   21
  40--59                                                        15   32
  \> 60                                                         22   47
  **Ethnicity (n = 47)**[\*](#t001fn001){ref-type="table-fn"}        
  Caucasians (whites)                                           6    13
  Blacks                                                        2    4
  Mestizo                                                       37   79
  Indigenous                                                    2    4
  **Formal education time (n = 47)**                                 
  \<1 year                                                      10   21
  1--8 years                                                    29   62
  9--12 years                                                   8    17
  \>12 years                                                    0    0
  **Marital status (n = 47)**                                        
  Single                                                        9    19
  Married                                                       26   56
  Widower                                                       10   21
  Divorced                                                      2    4
  **Origin (n = 47)**                                                
  Capital city (Manaus)                                         11   23
  Amazonas (interior)                                           30   64
  Other Northern states                                         6    13
  **Penectomy type (n = 47)**                                        
  Partial                                                       32   68
  Total                                                         15   32
  **Tumor location (n = 43)**                                        
  Glans                                                         7    16
  Foreskin                                                      1    2
  Glans and Foreskin                                            25   58
  Glans, Foreskin and base                                      7    17
  All over the organ                                            3    7
  **Predominant gross finding (n = 40)**                             
  Ulcerated                                                     15   37
  Verruciform                                                   19   48
  Ulcerated and Verruciform                                     6    15
  **Tumor subtype (n = 20)**                                         
  Basaloid                                                      5    25
  Warty                                                         2    10
  Cuniculatum                                                   1    5
  Sarcomatoid                                                   1    5
  Usual                                                         11   55
  **TNM \[**[@pone.0232474.ref030]**\] (n = 32)**                    
  pTx                                                           1    3
  pT1 --pT2                                                     18   56
  pT3- pT4                                                      13   41
  **Histological grade (n = 33)**                                    
  Grade I                                                       4    12
  Grade II                                                      19   58
  Grade III                                                     10   30
  **Lymphadenectomy (n = 47)**                                       
  Yes                                                           13   28
  No                                                            34   72
  **Metastasis (n = 40)**                                            
  Yes                                                           12   29
  No                                                            28   71
  **Follow up (n = 47)**                                             
  Dead                                                          18   38
  Alive                                                         29   62

\*self-declared; n: Absolute frequency; %: Relative frequency

All cases were diagnosed as squamous cell carcinoma. Of the 47 patients with PC, we were able to review and reclassify only 20 patients according to the 2016 WHO classification \[[@pone.0232474.ref029]\]. The most common histology subtype was "usual" in 11/20 (55%). We could obtain tumor characteristic from the medical records for only 43 patients. 58% of tumors were located in the glans and foreskin and the predominant pattern of growth was verruciform (48%). Other clinical and pathological parameters can be appreciated in [Table 1](#pone.0232474.t001){ref-type="table"}.

In this study, 36% of the patient had a history of cancer in the family. 60% of the patients were smokers or ex-smokers and 64% had phimosis. 43% were circumcised, mostly in adulthood. 28% of the patients reported a history of sexually transmitted diseases once or several times in their adulthood ([Table 2](#pone.0232474.t002){ref-type="table"}).

10.1371/journal.pone.0232474.t002

###### Risk factors of the 47 patients diagnosed with penile cancer at Amazon---Brazil.

![](pone.0232474.t002){#pone.0232474.t002g}

  Risk factors                                 n    \%
  -------------------------------------------- ---- ----
  **Family history of cancer (n = 47)**             
  Yes                                          17   36
  No                                           30   64
  **Smoking History (n = 47)**                      
  Smoking / Ex-Smoking                         28   60
  No Smoking                                   19   40
  **Phimosis (n = 47)**                             
  Yes                                          30   64
  No                                           17   36
  **Postectomy (n = 30)**                           
  Yes                                          13   43
  No                                           17   57
  **Time of postectomy (n = 13)**                   
  Childhood                                    3    23
  Adulthood                                    10   77
  **Sexually transmitted diseases (n = 47)**        
  Yes                                          13   28
  No                                           34   72

n: Absolute frequency; %: Relative frequency

The prevalence of HPV is shown in [Table 3](#pone.0232474.t003){ref-type="table"}. HPV DNA was detected in 45% (21/47) of the patients with PC. HPV 16 was the most prevalent genotype 61% (13/21). The other 8 genotypes detected were HPV 6, 11, 42, 51, 53, 68 and 44/55. One patient had multiple co-infections; genotypes 16, 42, 44/55. The distribution of EBV and HPV among the patients with PC is shown in [Fig 1](#pone.0232474.g001){ref-type="fig"}. EBV infection was observed in 14 out of 47 patients (30%). Co-infection HPV/EBV was detected in 6 patients, four with HPV 16/EBV and two with HPV 6/EBV and HPV 53/EBV, each. The p16^INK4a^ overexpression was observed in three patients with co-infection HPV/EBV, all HPV 16.

![Distribution of HPV and EBV status among the patients with penile cancer at Amazon---Brazil.\
EBV: Epstein-Barr virus; HPV: Human papillomavirus.](pone.0232474.g001){#pone.0232474.g001}

10.1371/journal.pone.0232474.t003

###### HPV infection prevalence and genotyping at 47 patients diagnosed with penile cancer at Amazon---Brazil.

![](pone.0232474.t003){#pone.0232474.t003g}

  ------------------------------ ------- -------
  **Virus infection (n = 47)**   **n**   **%**
  HPV---Positive                 21      45
  HPV---Negative                 26      55
  **HPV genotyping (N = 21)**    **n**   **%**
  6                              1       5
  11                             1       5
  16                             13      61
  44/55                          1       5
  51                             2       9
  53                             1       5
  68                             1       5
  16,42,44/55                    1       5
  ------------------------------ ------- -------

n: Absolute frequency; %: Relative frequency

Association of p16^INK4a^ overexpression with clinical factors and HPV infection status are shown in [Table 4](#pone.0232474.t004){ref-type="table"}. Overexpression of p16^INK4a^ was found in 12 cases 46% (12/26). Patients with phimosis had 11 times more chance of having overexpression of p16^INK4a^ \[OR = 11 (95%CI 1.1--109.7); *p* = 0.04\]. The p16^INK4a^ overexpression was observed in the eight HPV 16 positive cases and in four HPV^-^. Other clinical factors were not significantly associated with HPV infection and p16^INK4a^ overexpression. HPV infection and p16^INK4a^ overexpression were also related to some histological subtypes, HPV infection being positive in the basaloid subtypes (45%) and negative in usual subtypes (81%) ([Table 4](#pone.0232474.t004){ref-type="table"}). Regarding p16^INK4a^ overexpression, of the 11 nonsmokers patients, eight presented over expression of p16^INK4a^ while only four patients of the 15 smokers were with p16^INK4a^ overexpression \[OR = 0.13 (95%CI 0.02--0.780); p = 0.026\]. Notably, of the eight nonsmoker's patients with p16^INK4a^ overexpression, six had HPV 16 genotypes and the remaining two were negative for HPV. Among the four smoker's patients with p16^INK4a^ overexpression, two were HPV16 and two negative for HPV. HPV^+^ patients with PC had poorly differentiated carcinomas (Grade III) compared to HPV^-^ patients with PC \[OR = 0.07 95%CI 0.01--0.047; *p* = 0.005\].

10.1371/journal.pone.0232474.t004

###### Relationship between p16^INK4a^ overexpression, HPV infection status, EBV infection status and clinical factors at 47 patients diagnosed with penile cancer.

![](pone.0232474.t004){#pone.0232474.t004g}

  Variable                     p16   HPV   EBV                                                                                                                                                                                               
  ---------------------------- ----- ----- ----- ------ ---------------- -------------------------------------------- ---- ---- ---- ------ -------------- -------------------------------------------- ---- ---- ---- ------ -------------- -------
  **Age (years)**                                                                                                                                                                                                                            
  ≤ 45                         8     5     3                                                                          13   8    5                                                                       13   9    4                          
  \> 45                        18    9     9     0.36   (0.05--2.34)     0.284                                        34   18   16   1.40   (0.38--5.24)   0.597                                        34   24   10   0.94   (0.23--3.76)   0.927
  **Smoking or Ex Smoking**                                                                                                                                                                                                                  
  No                           11    3     8                                                                          19   11   8                                                                       19   13   6                          
  Yes                          15    11    4     0.13   (0.02--0.78)     0.026[\*](#t004fn002){ref-type="table-fn"}   28   15   13   1.19   (0.37--3.86)   0.770                                        28   20   8    0.87   (0.24--3.08)   0.825
  **Phimoses**                                                                                                                                                                                                                               
  No                           8     7     1                                                                          17   10   7                                                                       17   11   6                          
  Yes                          18    7     11    11.0   (1.10--109.67)   0.041[\*](#t004fn002){ref-type="table-fn"}   30   16   14   1.25   (0.38--4.16)   0.716                                        30   22   8    0.67   (0.18--2.40)   0.535
  **Postectomy**                                                                                                                                                                                                                             
  No                           11    5     6                                                                          17   9    8                                                                       17   13   4                          
  Yes                          7     2     5     2.08   (0.27--15.77)    0.477                                        13   7    6    0.96   (0.23--4.10)   0.961                                        13   9    4    1.44   (0.28--7.34)   0.658
  **Histological grading**                                                                                                                                                                                                                   
  Grade I / II                 10    4     6                                                                          10   2    8                                                                       10   6    4                          
  Grade III/IV                 12    6     6     0.66   (0.12--3.63)     0.640                                        23   18   5    0.07   (0.01--0.46)   0.005[\*](#t004fn002){ref-type="table-fn"}   23   15   8    0.80   (0.17--3.68)   0.775
  **Tumor subtype (n = 20)**                                                                                                                                                                                                                 
  Basaloid                     5     0     5                                                                          5    0    5                                                                       5    4    1                          
  Warty                        2     1     1                                                                          2    0    2                                                                       2    1    1                          
  Cuniculatum                  1     1     0                                                                          1    0    1                                                                       1    0    1                          
  Sarcomatoid                  1     0     1                                                                          1    0    1                                                                       1    1    0                          
  Usual                        10    7     3                             0.062                                        11   9    2                          0.009[\*](#t004fn002){ref-type="table-fn"}   11   7    4                          0.540
  **TNM (AJCC, 8°ed.)**                                                                                                                                                                                                                      
  T1 --T2                      10    5     5                                                                          19   10   9                                                                       19   13   6                          
  T3 --T4                      11    8     3     0.37   (0.06--2.30)     0.290                                        13   7    6    0.95   (0.23--3.91)   0,946                                        13   9    4    0.96   (0.20--4.42)   0,961
  **Lymphadenectomy**                                                                                                                                                                                                                        
  No                           16    8     8                                                                          34   17   17                                                                      34   25   9                          
  Yes                          10    6     4     0.66   (0.13--3.30)     0.619                                        13   9    4    0.44   (0.11--1.72)   0.190                                        13   8    5    1.73   (0.44--6.71)   0.424
  **Metastase**                                                                                                                                                                                                                              
  No                           16    7     9                                                                          29   15   14                                                                      29   20   9                          
  Yes                          9     6     3     0.38   (0.07--2.13)     0.250                                        12   7    5    0.71   (0.19--2.97)   0.700                                        12   8    4    1.11   (0.26--4.66)   0.886
  **Death**                                                                                                                                                                                                                                  
  No                           12    7     5                                                                          29   17   12                                                                      29   22   7                          
  Yes                          14    7     7     0.71   (0.15--3.38)     0.671                                        18   9    9    1.41   (0.43--4.62)   0.564                                        18   11   7    2.00   (0.55--7.14)   0.286
  **EBV**                                                                                                                                                                                                                                    
  Negative                     17    9     8                                                                          33   18   15                                                                      \-   \-   \-                         
  Positive                     9     5     4     0.9    (0.17--4.56)     0.899                                        14   8    6    0.90   (0.26--3.17)   0.870                                        \-   \-   \-   \-     \-             \-
  **HPV**                                                                                                                                                                                                                                    
  Negative                     11    7     4                                                                          \-   \-   \-                                                                      26   18   8                          
  Positive                     15    7     8     2.0    (0.40--9.83)     0.394                                        \-   \-   \-   \-     \-             \-                                           21   15   6    0.90   (0.25--3.17)   0.870
  **HPV Genotype**                                                                                                                                                                                                                           
  HR-HPV                       11    3     8                                                                          \-   \-   \-                                                                      17   12   5                          
  LR-HPV                       4     4     0     \-     \-               \-                                           \-   \-   \-   \-     \-             \-                                           4    3    1    0.80   (0.06--9.66)   0.861

HPV: Human papillomavirus; HR-HPV: High-oncogenic risk; LR-HPV: Low oncogenic risk; EBV: Epstein-Barr virus; n: Absolute frequency; Odds Ratio (OR) were calculated by logistic regression.

\*statistically significant (*p*-value \< 0.05) and (*p*-value adjusted \< 0.05)

In the survival analysis, the follow-up time was 35.4 months/patient. The mortality rate during the study period was 38% (18/47). Survival analysis was performed by stratification of the patients into p16^INK4a+^ vs p16^INK4a-^, HPV^+^ vs HPV^-^, EBV^+^ vs EBV- and HPV/EBV co-infection vs no infection. Infection status of the deceased and survival patients is shown in [S1 Table](#pone.0232474.s004){ref-type="supplementary-material"}. There is no evidence of differences in survival of patients according to p16 overexpression (P~log\ rank~ = 0.753), HPV infection (P~log\ rank~ = 0.979), EBV infection (P~log\ rank~ = 0.106) and HPV/EBV co-infection (P~log\ rank~ = 0.318) ([Fig 2](#pone.0232474.g002){ref-type="fig"}). **P16 expression and overall mortalityHPV status and overall mortalityEBV status and overall mortalityHPV/EBV co-infection vs no infection and overall mortality**

![The y-axis represents the survival function and x-axis represents the follow-up length in days.\
Overall survival depending on p16^INK4a^ expression (A), HPV infection status (B), positive and negative for EBV (C) and HPV/EBV co-infection (D). EBV: Epstein-Barr virus; HPV: Human papillomavirus.](pone.0232474.g002){#pone.0232474.g002}

Discussion {#sec021}
==========

In the Northern region of Brazil, the mortality rate from PC has doubled in recent years according to INCA \[[@pone.0232474.ref005]\]. The state of Amazonas, the largest state in Brazil, covers a geographical area of 1,559,168.12 km^2^ and has about 4 million inhabitants. Half of the population lives in the capital city, Manaus while the other half is distributed irregularly in the rural regions with low density population with very poor access to health services \[[@pone.0232474.ref031]\].

The disease affects mainly men between the fifth and seventh decade of life \[[@pone.0232474.ref002],[@pone.0232474.ref006],[@pone.0232474.ref032]\]. In this study, the mean age of the diagnosis of PC was 57.4 years, with a higher prevalence in the age group below 59 years. However, young adults less than 30 years were also diagnosed with PC (9%). Other studies in the country have also reported the early occurrence of PC \[[@pone.0232474.ref004],[@pone.0232474.ref033]--[@pone.0232474.ref037]\]. The risk factors and carcinogenesis of PC among young adults is still not established. In this study, young patients were at an advanced stage of the disease. Half of them underwent total penectomy and had metastasis. Of the four young patients, one had co-infection HPV 6/EBV and one HPV 44/55. Two were HPV negative. Interestingly, none of them had high-risk HPV. This may suggest that there are other factors or genetic and molecular changes possibly involved in the development of PC in young adults.

In this study, most of the patients came from the interior of Amazonas and belong to riverside isolated populations with low levels of education and poor access to health services. Besides, they have poor knowledge about the disease and seek diagnosis at an advanced stage. This reality was also observed by Chalya et al. (2015) in Tanzania \[[@pone.0232474.ref038]\] and in Brazil by other groups \[[@pone.0232474.ref033]--[@pone.0232474.ref035],[@pone.0232474.ref039],[@pone.0232474.ref040]\].

PC usually begins with a superficial or ulcerated lesion on the glans and foreskin, but can also spread through the penile shaft and the scrotum \[[@pone.0232474.ref041]\]. In the current study, the initial lesion was diagnosed in the glans and/or prepuce in 76% of the cases similar to other studies \[[@pone.0232474.ref004],[@pone.0232474.ref038],[@pone.0232474.ref042]\]. Lesions were predominantly of the verruciform type followed by warts. The accumulation of smegma due to poor hygiene followed by probable irritation of the local is a favorable environment for several infections. Chronic inflammatory processes may progress to the development of lesions and if untreated, can lead to neoplasm \[[@pone.0232474.ref007]\].

In the present study, 70% (23/33) of the patient showed well and moderately differentiated tumors (Grade I/II) and was not associated with HPV infection (*adjusted p-value* = 0.006). Patients with HPV presented higher grade tumor. Histopathology grade is an important prognostic factor. Degree of poorly differentiated cell could indicate a worse prognosis of lesions. Our findings reinforced other studies observations \[[@pone.0232474.ref043],[@pone.0232474.ref044]\].

Phimosis, a well-known risk factor for the development of PC, was present in 64% of the patients. 43% were submitted to circumcision during adulthood. Adult circumcision is known to have no protective effect against the development of PC \[[@pone.0232474.ref045]\]. The univariate logistic regression showed that patients with phimosis had 11 times more chance of overexpression of p16^INK4a^ \[OR = 11 (95%CI 1.1--109.7); p = 0.04\]. Among men circumcised in adulthood, phimosis was strongly associated with development of invasive penile cancer, in concordance with the findings of Daling, et al. (2005) \[[@pone.0232474.ref046]\].

Of note, the presence of HPV in an individual does not mean that the individual will develop cancer. There are many risk factors that contribute to the development or not such as the environment and the genetic background of the individuals as well as the viral clearance capacity of the individual. PC can be HPV-mediated or not. Individuals HPV^-^ with phimosis and chronic inflammation often develop PC. Genetic and molecular changes associated with HPV^-^ PC leading to disturbance of the p14^ARF^/MDM2/p53 and/or p16^INK4a^/cyclin D/Rb pathways have been suggested as plausible mechanisms for the development of PC \[[@pone.0232474.ref047]\]. One study showed that there is silencing of the p16^INK4a^ gene through promoter hypermethylation in 15% of cases and over-expression of the polycomb group (PcG) gene BMI-1, which targets the INK4A/ARF locus, encoding both p16^INK4a^ and p14^ARF^, in 10% of cases. Another study have suggested that the inactivation of p14^ARF^/MDM2/p53 pathway as well as somatic mutation of the p53 gene and over-expression of MDM2 and mutation of p14^ARF^ may lead to the development of PC \[[@pone.0232474.ref048],[@pone.0232474.ref049]\].

Emerging interest regarding PC carcinogenesis is the association of oncogenic viruses co-infection. EBV is associated with several malignancies in humans and its involvement in PC is still controversial \[[@pone.0232474.ref050]--[@pone.0232474.ref052]\]. In this study, the prevalence of EBV was 30% and co-infection with HPV was 29%. Our study differs to the one conducted in Rio de Janeiro where the prevalence of EBV in penile malignancies was 46% and co-infection with HPV was 26% \[[@pone.0232474.ref017]\]. In cervical cancer, EBV has been suggested as a cofactor that facilitates the integration of the HPV16 genome, contributing to the development of cancer \[[@pone.0232474.ref020],[@pone.0232474.ref021]\].

The prevalence of HPV in invasive PC is approximately 45%, ranging from 30% to 75% according to the detection method, the population and type of sample analyzed \[[@pone.0232474.ref011],[@pone.0232474.ref017],[@pone.0232474.ref018],[@pone.0232474.ref040],[@pone.0232474.ref042],[@pone.0232474.ref053]--[@pone.0232474.ref055]\]. High-risk HPV genotype 16 was observed in 61% of HPV^+^ cases, reinforcing other studies observations \[[@pone.0232474.ref009],[@pone.0232474.ref056]\]. HPV 18, the second most common high-risk HPV \[[@pone.0232474.ref011]\], was not identified in this study. Low incidence of HPV 18 in PC has also been reported in the country \[[@pone.0232474.ref017],[@pone.0232474.ref040],[@pone.0232474.ref042],[@pone.0232474.ref054]\]. Of note, the prevalence of HPV 18 is also low in the female population of the Amazonas region \[[@pone.0232474.ref057],[@pone.0232474.ref058]\]. Interestingly, in one study of the Thailand population, only 1/65 patients with PC had HPV16 but high presence of HPV18 genotype (55%) was detected \[[@pone.0232474.ref059]\]. This can probably be explained due to geographical distribution of HPV genotypes.

The occurrence of viral co-infection between HPV genotypes 6, 16, 42, 44/55 and EBV was observed. One patient presented EBV/HPV 6 co-infection. Similar findings, EBV/HPV 6 had been described \[[@pone.0232474.ref018]\] suggesting a probable viral synergism in tumor development due to their similar tropism of epithelial cells \[[@pone.0232474.ref020],[@pone.0232474.ref021]\]. The association of EBV and carcinogenesis is still to be demonstrated with EBV genome or virus gene products within the tumor cell population \[[@pone.0232474.ref060]\]. HPV 6 is classified as low oncogenic risk and is related to condyloma \[[@pone.0232474.ref061]\]. However, it is a prominent feature in infections in cases of PC and has multiple co-infections with high-risk types \[[@pone.0232474.ref011],[@pone.0232474.ref062],[@pone.0232474.ref063]\].

The overexpression of p16^INK4a^, a surrogate sensitive marker of HPV in PC \[[@pone.0232474.ref016]\], still remains to correlate with prognostics \[[@pone.0232474.ref012]\]. Overexpression of P16^INK4a^ was observed in 12 cases (12/26, 46%). 66% (8/12) were from patients infected with HPV 16, reinforcing the role played by HPV16 in the oncogenic process.

Four HPV negative patients showed overexpression of p16^INK4a^ (4/12, 33%). Bleeker et al. (2009) in a systematic review, assumes that PC would be related to a pathway mediated by HPV infection and another due to different epigenetic changes in the absence of HPV and related to chronic inflammation \[[@pone.0232474.ref047]\]. Understanding the molecular processes involved in the onset and progression of the disease is fundamental for the prevention and treatment of this mutilating.

In this series of cases, the mortality rate during the study was 38%. Several studies tried to identify prognostic factors to manage the selection of patients at high risk for metastases in PC \[[@pone.0232474.ref064]--[@pone.0232474.ref068]\]. HPV infections as well as co-infection with EBV and p16^INK4a^ positivity were not predictive of survival of the patients with PC. Lymph node involvement is related to poor prognosis, with a 5-year survival of less than 40% \[[@pone.0232474.ref069],[@pone.0232474.ref070]\]. In this study, only 39% of the patients with PC had lymphadenectomy.

Limitations of the study were the difficulties inherent to the non-recording of clinical and histopathological data in medical records. Many biopsy samples fixed in paraffin blocks were missing for the IHC assay for the qualitative detection of the p16^INK4a^, reducing the sample size. In the state of Amazonas, usually patients seek care at an advanced stage of the disease and as soon as they complete their surgical treatment (partial or total penectomy) they return to their city and there is no follow-up.

HPV vaccination has been shown to be effective for HPV-related cancers and inclusion of young in the immunization programs against HPV is well established \[[@pone.0232474.ref071],[@pone.0232474.ref072]\]. In the Amazonas, the vaccination program for girls started in 2013 with the quadrivalent vaccine that protects against genotypes 6, 11, 16 and 18. In Brazil, the Ministry of Health only included young males (between 12 and 13 years old) in the vaccination HPV program in 2017. In the future, we expect that this action may reduce the incidence of PC and other HPV-related.

Conclusions {#sec022}
===========

In summary, our results show that patients with HPV^+^ PC have in general low grade tumors. Overexpression of p16^INK4a^ was correlated to the detection of HPV 16 DNA, reinforcing that it can be used as a marker to high-risk HPV genotype 16 infection as found in oropharyngeal cancers. EBV infection was observed in one-third of the patients with PC and the co-infection with HPV in a quarter. The knowledge of the etiology of penile cancer is far from definite. The individual role or synergisms of the known oncogenic viruses such as HPV and EBV at the onset of carcinogenic events are still not well defined. However, our data show the profile of these viral oncogenic infections and the reality of this neoplasm in individuals from the Brazilian Amazon.
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Reviewer \#1: The authors present tumor tissue analyzes from 47 patients with penile cancer. Samples were analyzed for the presence of HPV and EBV DNA by PCR. In addition p16 INK4a expression was evaluated by immunohistochemistry. The results roughly agree with those in the world literature. In the second sentence of the introduction the authors state: In Brazil, PC accounts for approximately 2.1% of all tumors in men being the highest incidence reported in the world (2.9-6.8 cases per 100,000 men-years). In the cited article, Brazil appears in the first place in the ranking of Latin America being surpassed in the world by Romania and Uganda. The authors presented a survival curve showing a better prognosis for Ebv- patients when compared to Ebv +. I would like they comment on why this result.

Reviewer \#2: The present study is about penile cancer and oncogenic viruses HPV and EBV and their relationship with clinical and pathological characteristics. The work is important because penile carcinoma is an uncommon neoplasm, although in some regions of the world, such as Brazil, its incidence is higher, and because of the importance of exploring another possible etiological or risk factor, that is, EBV. HPV in penile cancer has been recognized in almost 50% of the cases. In contrast, the presence and biological and clinical relevance of EBV in penile cancer have not been sufficiently studied. However, it is necessary to review the scope of the findings and analyze the concomitant presence of both viruses and the clinical and pathological characteristics of the patients, in order to define the possible relationship of EBV in penile cancer. In this sense, it is necessary to consider the following observations.

Title

"HIGH PREVALENCE OF HPV WITH OVEREXPRESSION OF p16 INK4A PROTEIN AND CO-INFECTION WITH EBV IN PENILE CANCER -- A SERIES OF CASES FROM BRAZIL AMAZON". The title suggests that the authors found a higher prevalence of HPV than the one reported worldwide and that there is a concomitant presence of EBV infection in HPV positive cases. However, the data obtained does not reflect this. I suggest that the title should be modified to reflect in the best way the scope of the study and the results obtained.

Abstract

Line 27. It reads "Epstein Baar"; it should read "Epstein-Barr".

Line 57. It reads "Con-infection"; it should read "co-infection".

The conclusion states that "p16 INK4a positivity presented a high correlation to HPV 16 DNA detection, reinforcing its use as a surrogate marker for HPV-driven cancers." This is not a novel finding. Thus, it is necessary to rewrite the conclusion in the abstract and the text after analyzing the group of concomitant HPV and EBV infection and EBV alone.

Introduction

Line 56-58. It is necessary to update the references about epidemiological data of penile carcinoma, since the only reference is from 2010, and there are recent works on this issue.

Line 69-70. Concerning HPV prevalence in penile carcinoma, it is necessary to complement and or compare the most recent data worldwide (Bruni 2017; Alemany 2016; Olesen 2019).

Line 80-86. It is important to describe the oncogenic role of EBV in cancer, as currently known, and the cell types affected by such viruses. The relationship between EBV and HPV in carcinogenesis is described in various papers; one of them is a review by Guidry and Scott (doi:10.1016/j.virusres.2016.11.002.). It is necessary to expand the references about the oncogenic role of EBV in epithelial carcinogenesis.

Line 87-88. It is necessary to describe in a better way the rationale or the relevance of the work, emphasizing the study of EBV and HPV, and the few studies specifically in penile carcinoma.

Materials and Methods

Line 112-113. Specify the size of the b-globin product.

Line 126. What is the reason to do specific E7 HPV 16 and 18? The results and discussion about this detection are not mentioned. Besides, the genotyping by papillocheck test was used. The rationale to detect E7 is not indicated.

Line 171. It is necessary to indicate why only 21/47 samples were analyzed.

Results

Tables 1 and 2 could be merged.

Line 210-211. In patients with EBV and HPV co-infection, the relationship with p16 overexpression should be described.

Table 3. Include the information about the expression of p16.

Line 215-216. It would be important to evaluate the presence of HPV newly (with a different method, if possible) in the positive cases of p16, which were initially identified as negative for HPV DNA.

Line 219-220. Smoking and HPV presence are relatively excluding factors, at least in HNCSS. The relationship between overexpression of p16 and smoking was identified; however, it was not so with the presence of HPV. The analysis was made with all genotypes identified (low and high risk). What is the relationship between smoking and high-risk HPV presence?

Line 223-228. It is necessary to describe the survival analysis of the group with co-infection of HPV and EBV since the analysis was only made individually, and an important issue (since the title of the study) is the co-infection of EBV and HPV. The result should be discussed.

Table 4. This table could be simplified by removing the percentages (leaving the frequencies), and adding the EBV presence in the header row and respective analysis.

Discussion

Line 251. The metastasis analysis should be extended. This issue has been addressed in head and neck carcinomas HPV negative versus positive, and also in nasopharyngeal carcinomas EBV positive, as well as prognosis factors associated.

Line 252-253. The result about HPV in young men contrasts with a recent article ([doi.org/10.1186/s12879-019-4696-6](http://doi.org/10.1186/s12879-019-4696-6)), reporting that at least 50% of men under 45 years have HPV. It is important to extend the discussion about the characteristics of penile cancer in young men and contrast the results with other reports.

Line 258. Change the capital letters in the author\'s name cited.

Line 268. According to the data in Table 4, tumor grade III is associated with HPV presence. Improve the description of this finding and mention the concordance with previous works.

Line 275-276. How could you explain the relationship between phimosis and overexpression of p16?

Line 279-285. The relationship between EBV and HPV should be expanded. Although the relation between EBV and HPV in penile cancer is incipient, the relationship is described in another HPV-related cancer. Several articles have described the association between expression of p16 and EBV in other neoplasms (Doi: 10.1002/hed.24258. [doi.org/10.1016/j.ijrobp.2017.06.1473](http://doi.org/10.1016/j.ijrobp.2017.06.1473). [doi.org/10.3389/fonc.2018.00113](http://doi.org/10.3389/fonc.2018.00113)), and this is not described in the discussion.

Line 289-290. The absence of HPV 18 in penile carcinoma is consistent with other works. ([doi.org/10.1186/s12879-019-4696-6](http://doi.org/10.1186/s12879-019-4696-6)), and in contrast with the findings in other regions (DOI: 10.1002/jmv.20703).

Line 295. Describe more broadly the possible mechanisms for the synergistic effect of HPV 6 and EBV.

Line 302-303. What other genotypes (different to HPV 16) were present in the p16 positives cases?

Line 304. Change the capital letters of the author\'s name cited.

Line 313, Figure 2. The correlation between p16 overexpression and survival has been addressed in other neoplasms. The authors should review the impact of the clinical stage on survival. Did you consider the local and advanced stages for survival analysis?

Finally, the authors should discuss the limitations of the study. For example, the number of p16 samples analyzed, if the size (3-5 mm) of samples analyzed was adequate for the detection of the viruses, p16, and pathological characteristics.

One issue not mentioned is the presence of HPV without relation to penile carcinogenesis. Therefore, it is important to describe the p16 overexpression as a subrogate biomarker of carcinogenesis induced by high-risk HPV. The analysis of EBV dependent and independent of HPV should be extended and, consequently, the discussion.
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Reviewer \#1:

The authors present tumor tissue analyzes from 47 patients with penile cancer. Samples were analyzed for the presence of HPV and EBV DNA by PCR. In addition, p16 INK4a expression was evaluated by immunohistochemistry. The results roughly agree with those in the world literature. In the second sentence of the introduction the authors state: In Brazil, PC accounts for approximately 2.1% of all tumors in men being the highest incidence reported in the world (2.9-6.8 cases per 100,000 men-years). In the cited article, Brazil appears in the first place in the ranking of Latin America being surpassed in the world by Romania and Uganda.

We agree and have corrected in the texts. (Line 57-58)

The authors presented a survival curve showing a better prognosis for Ebv- patients when compared to Ebv +. I would like they comment on why this result.

We agree with the reviewer that there is a trend due to the sudden drop of the survival curve. However, the comparison showed no difference (Plog rank = 0.106).
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Reviewer \#2:

The present study is about penile cancer and oncogenic viruses HPV and EBV and their relationship with clinical and pathological characteristics. The work is important because penile carcinoma is an uncommon neoplasm, although in some regions of the world, such as Brazil, its incidence is higher, and because of the importance of exploring another possible etiological or risk factor, that is, EBV. HPV in penile cancer has been recognized in almost 50% of the cases. In contrast, the presence and biological and clinical relevance of EBV in penile cancer have not been sufficiently studied. However, it is necessary to review the scope of the findings and analyze the concomitant presence of both viruses and the clinical and pathological characteristics of the patients, in order to define the possible relationship of EBV in penile cancer. In this sense, it is necessary to consider the following observations.

Title

"HIGH PREVALENCE OF HPV WITH OVEREXPRESSION OF p16 INK4A PROTEIN AND CO-INFECTION WITH EBV IN PENILE CANCER -- A SERIES OF CASES FROM BRAZIL AMAZON". The title suggests that the authors found a higher prevalence of HPV than the one reported worldwide and that there is a concomitant presence of EBV infection in HPV positive cases. However, the data obtained does not reflect this. I suggest that the title should be modified to reflect in the best way the scope of the study and the results obtained.

We agree and have rewritten the title.

PRESENCE OF HPV WITH OVEREXPRESSION OF p16 INK4A PROTEIN AND EBV INFECTION IN PENILE CANCER -- A SERIES OF CASES FROM BRAZIL AMAZON

Abstract

Line 27. It reads "Epstein Baar"; it should read "Epstein-Barr".

We have corrected in the texts. (Line 29)

Line 57. It reads "Con-infection"; it should read "co-infection".

We have corrected in the texts. (Line 51-52)

The conclusion states that "p16 INK4a positivity presented a high correlation to HPV 16 DNA detection, reinforcing its use as a surrogate marker for HPV-driven cancers." This is not a novel finding. Thus, it is necessary to rewrite the conclusion in the abstract and the text after analyzing the group of concomitant HPV and EBV infection and EBV alone.

We totally agree and have brought the necessary changes. (Line 51-52)

Introduction

Line 56-58. It is necessary to update the references about epidemiological data of penile carcinoma, since the only reference is from 2010, and there are recent works on this issue.

We have brought the necessary changes. (Line 55-57)

Line 69-70. Concerning HPV prevalence in penile carcinoma, it is necessary to complement and or compare the most recent data worldwide (Bruni 2017; Alemany 2016; Olesen 2019).

We have brought the necessary changes. (Line 69-71)

Line 80-86. It is important to describe the oncogenic role of EBV in cancer, as currently known, and the cell types affected by such viruses. The relationship between EBV and HPV in carcinogenesis is described in various papers; one of them is a review by Guidry and Scott (doi:10.1016/j.virusres.2016.11.002.). It is necessary to expand the references about the oncogenic role of EBV in epithelial carcinogenesis.

We have corrected accordingly. (Line 81-88)

Line 87-88. It is necessary to describe in a better way the rationale or the relevance of the work, emphasizing the study of EBV and HPV, and the few studies specifically in penile carcinoma.

We totally agree and have brought the necessary changes. (Line 89-90)

Materials and Methods

Line 112-113. Specify the size of the b-globin product.

We have provided in the text. (Line 115-117)

Line 126. What is the reason to do specific E7 HPV 16 and 18? The results and discussion about this detection are not mentioned. Besides, the genotyping by PapilloCheck test was used. The rationale to detect E7 is not indicated.

Reply

As PapilloCheck is a very expensive test, we have chosen to primarily screen the presence of HPV followed by typing specifically for HPV16 and HPV18. All of the samples that were negative for HPV16 and HPV18 were screen by PapilloCheck test to reduce the cost of typing.

Line 171. It is necessary to indicate why only 21/47 samples were analyzed.

Reply

We believe that there is misunderstanding here. We did already explain in the text. 21 samples were not available for pre-analytical analysis due to poor quality keeping of the samples.

Results

Tables 1 and 2 could be merged.

We do agree but merging both tables 1 and 2 will be heavy and confusing.

Line 210-211. In patients with EBV and HPV co-infection, the relationship with p16 overexpression should be described.

We have provided in the text. (Line 223-224)

Table 3. Include the information about the expression of p16.

Reply

As we did for only 26 samples, we did not include in the Table 3 to avoid confusion, but we describe in text.

Line 215-216. It would be important to evaluate the presence of HPV newly (with a different method, if possible) in the positive cases of p16, which were initially identified as negative for HPV DNA.

Reply

The four samples that were positive for p16 and negative for HPV were again tested for the presence of HPV16 and HPV18 by real-time PCR and continued to be negative.

Line 219-220. Smoking and HPV presence are relatively excluding factors, at least in HNCSS. The relationship between overexpression of p16 and smoking was identified; however, it was not so with the presence of HPV. The analysis was made with all genotypes identified (low and high risk). What is the relationship between smoking and high-risk HPV presence?

Reply

We have rewritten in the result section to avoid confusion. There was no relationship between smoking and high-risk HPV presence. As it can be seen that the driving force for the presence of p16 is mostly dependent on the presence of HPV and independent of the smoking status. (Line 232-238)

Line 223-228. It is necessary to describe the survival analysis of the group with co-infection of HPV and EBV since the analysis was only made individually, and an important issue (since the title of the study) is the co-infection of EBV and HPV. The result should be discussed.

Thank you for pointing this lack. We have performed the analysis and is shown in Figure 2D. The comparison showed no difference P log rank=0.318. We also included a S1 Table showing the infection status of the deceased and survived patients. (Line 240-241)

Table 4. This table could be simplified by removing the percentages (leaving the frequencies) and adding the EBV presence in the header row and respective analysis.

We have brought the necessary changes.

Discussion

Line 251. The metastasis analysis should be extended. This issue has been addressed in head and neck carcinomas HPV negative versus positive, and also in nasopharyngeal carcinomas EBV positive, as well as prognosis factors associated.

Reply

As our study is only focused on penile cancer, we did not compare with other types of cancers as we believe that the developing mechanisms could be different. For this reason, we did not extend the discussion.

Line 252-253. The result about HPV in young men contrasts with a recent article ([doi.org/10.1186/s12879-019-4696-6](http://doi.org/10.1186/s12879-019-4696-6)), reporting that at least 50% of men under 45 years have HPV. It is important to extend the discussion about the characteristics of penile cancer in young men and contrast the results with other reports.

Reply

We agree to disagree because of the sample size which makes it difficult to compare. In the study stated, there were only 8 patients under 45 years old and four of them were positive for HPV. In our study we had 13 patients under 45 years old and five (38%) were positive for HPV.

Line 258. Change the capital letters in the author\'s name cited.

We have corrected in the texts. (Line 259)

Line 268. According to the data in Table 4, tumor grade III is associated with HPV presence. Improve the description of this finding and mention the concordance with previous works.

We have added one more reference. (Line 292)

Line 275-276. How could you explain the relationship between phimosis and overexpression of p16?

We have provided in the discussion. (Line 300-312)

Line 279-285. The relationship between EBV and HPV should be expanded. Although the relation between EBV and HPV in penile cancer is incipient, the relationship is described in another HPV-related cancer. Several articles have described the association between expression of p16 and EBV in other neoplasms (Doi: 10.1002/hed.24258. [doi.org/10.1016/j.ijrobp.2017.06.1473](http://doi.org/10.1016/j.ijrobp.2017.06.1473). [doi.org/10.3389/fonc.2018.00113](http://doi.org/10.3389/fonc.2018.00113)), and this is not described in the discussion.

Reply

As cited previously (Answer Line 252). We have focus mainly on penile cancer. Considering that in other studies with penile cancer the HPV and EBV status were not predictive of outcome and we believe that the developing mechanisms could be different for another cancer.

Line 289-290. The absence of HPV 18 in penile carcinoma is consistent with other works. ([doi.org/10.1186/s12879-019-4696-6](http://doi.org/10.1186/s12879-019-4696-6)), and in contrast with the findings in other regions (DOI: 10.1002/jmv.20703).

We have included in the text. (Line 326-329)

Line 295. Describe more broadly the possible mechanisms for the synergistic effect of HPV 6 and EBV.

We included in the text. (Line 333)

Line 302-303. What other genotypes (different to HPV 16) were present in the p16 positives cases?

We have described in the result section. (Line 229-229)

Line 304. Change the capital letters of the author\'s name cited.

We have corrected in the texts. (Line 342)

Line 313, Figure 2. The correlation between p16 overexpression and survival has been addressed in other neoplasms. The authors should review the impact of the clinical stage on survival. Did you consider the local and advanced stages for survival analysis?

Reply

We have included in the text. However, we did stratify the patients according to the local and advanced stages as our sample size is small. And stratification will further reduce the sample and will not have any power to detect any difference according to our statistician. (Line 350-351)

Finally, the authors should discuss the limitations of the study. For example, the number of p16 samples analyzed, if the size (3-5 mm) of samples analyzed was adequate for the detection of the viruses, p16, and pathological characteristics.

We have described in the discussion section. And we also described in the materials and methods section and Supporting Information (S2 PROTOCOL - Immunohistochemistry for p16INK4a).

One issue not mentioned is the presence of HPV without relation to penile carcinogenesis. Therefore, it is important to describe the p16 overexpression as a surrogate biomarker of carcinogenesis induced by high-risk HPV. The analysis of EBV dependent and independent of HPV should be extended and, consequently, the discussion.

We have described in the discussion section.

Sincerely yours,

Yours faithfully,

Valquiria do Carmo Alves Martins

On behalf of all authors
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